OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Tokenizing loops of antibodies	255
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	160
Correction	157
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	132
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	128
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	124
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	90
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	86
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	85
Correction	84
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	83
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	72
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	63
An antibody developability triaging pipeline exploiting protein language models	63
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	61
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	56
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	54
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	54
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	50
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	49
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	48
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	45
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	45
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	45
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	43

The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	43
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	43
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	38
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	38
Impact of IgG subclass on monoclonal antibody developability	38
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	36
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	34
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	34
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	33
Antibodies to watch in 2024	33
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions	32
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG ₁ antibody	31
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	30
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	28
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	28
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	27
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO	27
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	27
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	27
Quantifying antibody binding: techniques and therapeutic implications	26
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	26
Discovery of broadly neutralizing V _H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	26
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	26
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	25
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	25
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	25
Cost and supply considerations for antibody therapeutics	25
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	24
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	24
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	24
Evolution of phage display libraries for therapeutic antibody discovery	23
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	23
Antibodies to watch in 2026	23
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	23
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	23
Correction	23
A versatile design platform for glycoengineering therapeutic antibodies	22
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	22
Electrostatic properties of human germlines and biodistribution of small biologics	22
A glyco-engineering approach for site-specific conjugation to Fab glycans	22
Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis	22
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	21
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	21
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	21
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	21
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	21
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	20
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	20
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	20
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	19

Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	19
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	19
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	19
Leveraging multi-modal feature learning for predictions of antibody viscosity	18
Multidimensional maturation of antibody variable domains with machine-learning assistance	18
Engineering death resistance in CHO cells for improved perfusion culture	18
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	18
Reduction of monoclonal antibody viscosity using interpretable machine learning	17
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	17
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	17
Predicting purification process fit of monoclonal antibodies using machine learning	17
Structural and biochemical differences between non-catalytic and catalytic antibodies	17
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	17
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	17
Alpseq : an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing	16
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	16
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	16
Physics-based surface patch analysis for prediction of hydrophobic contribution to viscosity of mAbs	16
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	16
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	16
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	16
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	15
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	15
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	15
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	15
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	15
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	15
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	14
Correction	14
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	14